Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 9/20 | 0.53 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 8/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.53 |
| ▸ | CDK9 | P50750 | 4/20 | 0.53 |
| ▸ | FLT3 | P36888 | 3/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 4/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.50 |
| ▸ | CDK7 | P50613 | 3/20 | 0.50 |
| ▸ | CCNH | P51946 | 3/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.50 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2546356 | 0.93 | CDK2 (0.53) | ACVR1CAMK2DCDK2CCNA2CCNT1 | |
| SCHEMBL2543938 | 0.90 | ACVR1 (0.61) | ACVR1CDK2CCNA2CCNT1CDK9 | |
| SCHEMBL2544927 | 0.90 | JAK2 (0.56) | ACVR1CAMK2DCDK2FLT3CCNE1 | |
| SCHEMBL2542794 | 0.86 | CAMK2D (0.56) | ACVR1CAMK2DCDK2CCNA2CCNT1 | |
| SCHEMBL2546577 | 0.83 | ACVR1 (0.57) | ACVR1CDK2CCNA2CCNT1CDK9 | |
| SCHEMBL2543346 | 0.82 | MKNK2 (0.51) | CDK2CCNA2CCNT1CDK9CDK1 | |
| SCHEMBL2542388 | 0.81 | CAMK2D (0.53) | ACVR1CAMK2DCDK2CCNA2CCNT1 | |
| SCHEMBL2540221 | 0.81 | CDK2 (0.67) | ACVR1CAMK2DCDK2CCNA2CCNT1 | |
| SCHEMBL2542950 | 0.81 | ACVR1 (0.61) | ACVR1CAMK2DCDK2CCNT1CDK9 | |
| SCHEMBL2542426 | 0.79 | SYK (0.46) | ACVR1CDK2CCNA2CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | LUO YING (CN) | 2014-10-09 | — | — | US | claimed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | claimed |
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | LUO YING (CN) | 2014-10-09 | — | — | US | disclosed |
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | MAP3K20, MAP3K1, MAP3K2 | ACVR1 2914/4885CAMK2D 239/4885CDK2 89/4885 |
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | NFKBIA, IRAK1, IRAK3 | ACVR1 2844/4885CAMK2D 38/4885CDK2 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.